Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Accumulated Expenses: 2015-2025

Historic Other Accumulated Expenses for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $170,000.

  • Spyre Therapeutics' Other Accumulated Expenses fell 67.68% to $170,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $170,000, marking a year-over-year decrease of 67.68%. This contributed to the annual value of $501,000 for FY2024, which is 2.66% up from last year.
  • Spyre Therapeutics' Other Accumulated Expenses amounted to $170,000 in Q3 2025, which was down 29.75% from $242,000 recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Other Accumulated Expenses ranged from a high of $1.1 million in Q2 2021 and a low of $170,000 during Q3 2025.
  • For the 3-year period, Spyre Therapeutics' Other Accumulated Expenses averaged around $355,333, with its median value being $371,000 (2025).
  • As far as peak fluctuations go, Spyre Therapeutics' Other Accumulated Expenses skyrocketed by 97.82% in 2022, and later tumbled by 67.68% in 2025.
  • Spyre Therapeutics' Other Accumulated Expenses (Quarterly) stood at $783,000 in 2021, then slumped by 57.85% to $330,000 in 2022, then soared by 47.88% to $488,000 in 2023, then climbed by 2.66% to $501,000 in 2024, then crashed by 67.68% to $170,000 in 2025.
  • Its last three reported values are $170,000 in Q3 2025, $242,000 for Q2 2025, and $371,000 during Q1 2025.